在阿尔茨海默病中血小板APP (粉样β前体蛋白) 处理的变化:可能的关联链
Hayder M Al-Kuraishy1, Ghassan M Sulaiman2, Hamdoon A Mohammed3
1Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Neuropsychopharmacology reports
|January 5, 2025
概括
活化血小板通过增加粉样蛋白-β (Aβ) 和粉样蛋白前体蛋白 (APP) 来促进阿尔茨海默病 (AD) 神经病理学. 针对血小板激活可能为AD提供一种新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,其特点是粉样β (Aβ) 和神经纤维状结病理.
- 粉样蛋白前体蛋白 (APP) 处理通过粉样蛋白 (BACE1/γ-分泌酶) 或非粉样蛋白 (ADAM10/α-分泌酶) 途径发生.
- 虽然α-分泌酶产生神经保护性sAPPα,但氨基基基因途径产生神经毒性Aβ.
研究的目的:
- 审查激活血小板在阿尔茨海默氏症病原发生中的作用.
- 探索血小板激活和AD神经病理学之间的联系.
- 讨论针对激活血小板作为阿尔茨海默病的潜在治疗方法.
主要方法:
- 文献综述侧重于阿尔茨海默病中的血小板功能.
- 分析了血小板激活,APP和Aβ之间的关系.
- 讨论针对血小板激活的治疗策略.
主要成果:
- 激活的血小板与AD病原发生有关,并增加了血小板激活.
- 血小板是循环APP和Aβ的主要来源,有助于AD神经病理.
- 血小板在突触可塑性和神经元分化中起着生理作用,但当过度激活时,会导致AD.
结论:
- 活化血小板和阿尔茨海默氏症神经病理学之间存在显著的联系.
- 向激活血小板可能是一个有希望的策略,以减轻AD病理.
- 对血小板-AD相互作用的进一步研究可能会揭示新的治疗点.
相关概念视频
01:26Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
03:03Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
01:22Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161